MA46712A - Combinaisons d'inhibiteurs de fgfr4 et de chélateurs de l'acide biliaire - Google Patents

Combinaisons d'inhibiteurs de fgfr4 et de chélateurs de l'acide biliaire

Info

Publication number
MA46712A
MA46712A MA046712A MA46712A MA46712A MA 46712 A MA46712 A MA 46712A MA 046712 A MA046712 A MA 046712A MA 46712 A MA46712 A MA 46712A MA 46712 A MA46712 A MA 46712A
Authority
MA
Morocco
Prior art keywords
combinations
acid chelators
fgfr4 inhibitors
biliary acid
biliary
Prior art date
Application number
MA046712A
Other languages
English (en)
Inventor
Robin Alec Fairhurst
Porta Diana Graus
Jacqueline Kinyamu-Akunda
Andreas Joerg Mahl
Luigi Manenti
Andreas Weiss
Armin Wolf
Kuno Wuersch
Original Assignee
Novartis Ag
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Novartis Ag filed Critical Novartis Ag
Publication of MA46712A publication Critical patent/MA46712A/fr

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
    • A61K31/496—Non-condensed piperazines containing further heterocyclic rings, e.g. rifampin, thiothixene or sparfloxacin
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
    • A61K31/505—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim
    • A61K31/506—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim not condensed and containing further heterocyclic rings
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/13—Amines
    • A61K31/14—Quaternary ammonium compounds, e.g. edrophonium, choline
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
    • A61K31/44—Non condensed pyridines; Hydrogenated derivatives thereof
    • A61K31/445—Non condensed piperidines, e.g. piperocaine
    • A61K31/4523—Non condensed piperidines, e.g. piperocaine containing further heterocyclic ring systems
    • A61K31/4545—Non condensed piperidines, e.g. piperocaine containing further heterocyclic ring systems containing a six-membered ring with nitrogen as a ring hetero atom, e.g. pipamperone, anabasine
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/74—Synthetic polymeric materials
    • A61K31/785—Polymers containing nitrogen
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K2300/00—Mixtures or combinations of active ingredients, wherein at least one active ingredient is fully defined in groups A61K31/00 - A61K41/00

Landscapes

  • Health & Medical Sciences (AREA)
  • Veterinary Medicine (AREA)
  • Chemical & Material Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • General Health & Medical Sciences (AREA)
  • Public Health (AREA)
  • Epidemiology (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Chemical & Material Sciences (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Organic Chemistry (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Medicines Containing Material From Animals Or Micro-Organisms (AREA)
  • Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
MA046712A 2016-11-02 2017-11-01 Combinaisons d'inhibiteurs de fgfr4 et de chélateurs de l'acide biliaire MA46712A (fr)

Applications Claiming Priority (1)

Application Number Priority Date Filing Date Title
US201662416222P 2016-11-02 2016-11-02

Publications (1)

Publication Number Publication Date
MA46712A true MA46712A (fr) 2019-09-11

Family

ID=60661908

Family Applications (1)

Application Number Title Priority Date Filing Date
MA046712A MA46712A (fr) 2016-11-02 2017-11-01 Combinaisons d'inhibiteurs de fgfr4 et de chélateurs de l'acide biliaire

Country Status (18)

Country Link
US (1) US11229643B2 (fr)
EP (1) EP3534902B1 (fr)
JP (2) JP7394623B2 (fr)
KR (1) KR102362648B1 (fr)
CN (2) CN109922804B (fr)
AU (1) AU2017354082B2 (fr)
BR (1) BR112019008787A2 (fr)
CA (1) CA3042475C (fr)
ES (1) ES2934341T3 (fr)
IL (1) IL266293B (fr)
MA (1) MA46712A (fr)
MX (1) MX2019005194A (fr)
PL (1) PL3534902T3 (fr)
PT (1) PT3534902T (fr)
RU (1) RU2742033C2 (fr)
SG (1) SG11201903911UA (fr)
WO (1) WO2018083603A1 (fr)
ZA (1) ZA201902744B (fr)

Families Citing this family (2)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US20180185341A1 (en) 2014-10-03 2018-07-05 Novartis Ag Use of ring-fused bicyclic pyridyl derivatives as fgfr4 inhibitors
CN112759593A (zh) 2019-11-01 2021-05-07 北京伯汇生物技术有限公司 桥环并醛基吡啶衍生物及其应用

Family Cites Families (29)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
AR059432A1 (es) 2006-02-10 2008-04-09 Genentech Inc Anticuerpos anti-fgf19 y metodos que usan estos
EP1918376A1 (fr) 2006-11-03 2008-05-07 Max-Planck-Gesellschaft zur Förderung der Wissenschaften e.V. FGFR4 favorise la résistance des cellules cancéreuses en réponse aux agents chimiothérapeutiques
SI2124884T1 (sl) * 2006-12-22 2019-09-30 Ironwood Pharmaceuticals, Inc. Pripravki, ki obsegajo sekvestrante žolčnih kislin, za zdravljenje motenj požiralnika
PE20090227A1 (es) 2007-04-02 2009-04-03 Genentech Inc Composiciones farmaceuticas que comprenden agentes anti-beta-klotho
US8524212B2 (en) 2007-10-24 2013-09-03 Mitsubishi Tanabe Pharma Corporation Prophylactic and/or therapeutic drug for nonalcoholic steatohepatitis
FR2933702A1 (fr) 2008-07-08 2010-01-15 Sanofi Aventis Antagonistes specifiques du recepteur fgf-r4
US20110212091A1 (en) 2008-09-03 2011-09-01 Licentia Ltd. Materials and methods for inhibiting cancer cell invasion
US20100330175A1 (en) 2009-06-24 2010-12-30 Jobdevairakkam Christopher N Cross-linked polyallylamine tablet core
EP2694551A1 (fr) 2011-04-07 2014-02-12 Genentech, Inc. Anticorps anti-fgfr4 et procédés d'utilisation
DK2776055T3 (en) 2011-08-17 2017-03-06 Ironwood Pharmaceuticals Inc TREATMENTS FOR GASTROINTESTINAL DISORDERS
LT2872491T (lt) 2012-07-11 2021-08-25 Blueprint Medicines Corporation Fibroblasto augimo faktoriaus receptoriaus inhibitoriai
KR20230164238A (ko) 2012-12-27 2023-12-01 엔지엠 바이오파마슈티컬스, 아이엔씨. 담즙산 항상성의 조절 및 담즙산 질환 및 질병의 치료 방법
WO2014105849A1 (fr) 2012-12-28 2014-07-03 Xoma (Us) Llc Anticorps spécifiques contre le fgfr4 et méthodes d'utilisation
WO2014165287A1 (fr) 2013-03-12 2014-10-09 The Translational Genomics Research Institute Clones d'hybridome et anticorps monoclonaux dirigés contre le facteur de croissance 4 des fibroblastes
JP6553589B2 (ja) 2013-03-15 2019-07-31 ダナ−ファーバー キャンサー インスティテュート，インコーポレイテッド ピリミド−ジアゼピノン化合物および障害の治療方法
AU2014228746B2 (en) 2013-03-15 2018-08-30 Celgene Car Llc Heteroaryl compounds and uses thereof
TW201605452A (zh) 2013-08-28 2016-02-16 安斯泰來製藥股份有限公司 以嘧啶化合物作爲有效成分之醫藥組成物
SI3057943T1 (en) 2013-10-18 2018-08-31 Eisai R&D Management Co., Ltd. Pyrimidine FGFR4 Inhibitors
JP6203954B2 (ja) 2013-10-25 2017-09-27 ノバルティス アーゲー Ｆｇｆｒ４阻害剤としての縮環二環式ピリジル誘導体
TW201612518A (en) 2014-01-17 2016-04-01 Sanofi Sa Methods of identifying patients suffering from liver cancer who will most likely benefit from a treatment with an antagonist anti-FGFR4 antibody
AU2015277438B2 (en) * 2014-06-16 2020-02-27 Ngm Biopharmaceuticals, Inc. Methods and uses for modulating bile acid homeostasis and treatment of bile acid disorders and diseases
ES2764418T3 (es) 2014-08-11 2020-06-03 Daiichi Sankyo Europe Gmbh Anticuerpo anti-FGFR4 humano
US20180185341A1 (en) * 2014-10-03 2018-07-05 Novartis Ag Use of ring-fused bicyclic pyridyl derivatives as fgfr4 inhibitors
WO2016064960A1 (fr) 2014-10-22 2016-04-28 Incyte Corporation Hétérocycles bicycliques utilisés en tant qu'inhibiteurs de fgfr4
WO2016134294A1 (fr) 2015-02-20 2016-08-25 Incyte Corporation Hétérocycles bicycliques utilisés en tant qu'inhibiteurs de fgfr4
ES2895769T3 (es) 2015-02-20 2022-02-22 Incyte Corp Heterociclos bicíclicos como inhibidores de FGFR
MA41551A (fr) 2015-02-20 2017-12-26 Incyte Corp Hétérocycles bicycliques utilisés en tant qu'inhibiteurs de fgfr4
JP2018509448A (ja) * 2015-03-25 2018-04-05 ノバルティス アーゲー 組合せ医薬
EP3095465A1 (fr) * 2015-05-19 2016-11-23 U3 Pharma GmbH Combinaison d'un inhibiteur de fgfr4 et d'un chélateur d'acides biliaires

Also Published As

Publication number Publication date
EP3534902B1 (fr) 2022-11-23
JP2022033766A (ja) 2022-03-02
US20200261444A1 (en) 2020-08-20
SG11201903911UA (en) 2019-05-30
CN109922804B (zh) 2023-11-17
JP7394623B2 (ja) 2023-12-08
ZA201902744B (en) 2021-08-25
AU2017354082B2 (en) 2023-07-27
IL266293B (en) 2022-07-01
BR112019008787A2 (pt) 2019-07-16
PT3534902T (pt) 2022-12-07
WO2018083603A1 (fr) 2018-05-11
JP2019533701A (ja) 2019-11-21
CA3042475A1 (fr) 2018-05-11
KR20190082256A (ko) 2019-07-09
IL266293A (en) 2019-06-30
RU2019116061A (ru) 2020-12-04
ES2934341T3 (es) 2023-02-21
CA3042475C (fr) 2024-01-16
US11229643B2 (en) 2022-01-25
PL3534902T3 (pl) 2023-03-27
CN109922804A (zh) 2019-06-21
RU2742033C2 (ru) 2021-02-01
MX2019005194A (es) 2019-08-05
RU2019116061A3 (fr) 2020-12-04
AU2017354082A1 (en) 2019-05-23
EP3534902A1 (fr) 2019-09-11
CN117257800A (zh) 2023-12-22
KR102362648B1 (ko) 2022-02-11

Similar Documents

Publication Publication Date Title
MA44991A (fr) Polythérapies d'inhibiteurs de hdac et d'inhibiteurs de pd-1
MA49903A (fr) Sulfonylureés et sulfonylthioureés en tant qu'inhibiteurs de nlrp3
MA41999A (fr) Compositions d'acide obéticholique et procédés d'utilisation
MA44990A (fr) Polythérapies d'inhibiteurs de hdac et d'inhibiteurs de pd-l1
MA46954A (fr) Méthodes de traitement d'états inflammatoires
DK3743411T3 (da) Herbicidt virksomt 3-phenylisoxazolin-5-carboxamider af cyclopentenylcarbonsyrederivater
MA46481A (fr) Compositions d'oligonucléotides et méthodes associées
DK3497103T3 (da) Pyridopyrimdinon-cdk2/4/6-inhibitorer
MA46525A (fr) Anticorps anti-lag-3 et compositions
MA44725A (fr) Formulations d'un inhibiteur de lsd1
MA45192A (fr) Traitement d'association
MA44659A (fr) Anticorps anti-tim-3 et compositions
MA51616A (fr) Inhibiteurs d'adn-pk
MA44955A (fr) Anticorps anti-tau et leurs méthodes d'utilisation
MA47179A (fr) Composition d'acide dicarboxylique mannuronique
DK3578547T3 (da) Sulfonylureaer og relaterede forbindelser og brug af samme
MA41252A (fr) Formes solides d'un inhibiteur d'ask 1
DK3269716T3 (da) Hidtil ukendte forbindelser og farmaceutiske sammensætninger deraf til behandling af inflammatoriske lidelser
MA49726A (fr) Formulation d'anticorps anti-cgrp
MA40775A (fr) Dérivé d'acide 4-(4-(4-phényluréido-naphtalén -1-yl) oxy-pyridin-2-yl) amino-benzoïque utilisé en tant qu'inhibiteur de la kinase p38
MA45688A (fr) Compositions et procédés de potentialisation d'agents antimicrobiens
DK3510049T3 (da) Varianter af sur alfa-glucosidase og anvendelser deraf
DK3388427T3 (da) Derivater af dolastatin 10 og auristatiner
DK3078365T3 (da) Solubiliseringsmidler og vandige sammensætninger omfattende disse
MA47669A (fr) Structure cristalline de gremlin-1 et anticorps inhibiteur